Dicerna's approach offers strong advantages over conventional RNAi

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using a proprietary RNA interference (RNAi) technology platform, which the Company believes improves upon existing RNAi technologies, to build a broad pipeline in these therapeutic areas. 

Learn more.